4.7 Review

Mitochondria as a Therapeutic Target in Heart Failure

期刊

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jacc.2012.08.1021

关键词

cardiomyocytes; heart failure; mitochondria

资金

  1. National Institutes of Health [K02 HL107448, R01 HL104181, 1P01 HL108795]
  2. Bayer Schering Pharma AG
  3. Debio-Pharm S.A.
  4. Medtronic
  5. Novartis Pharma AG
  6. Otsuka Pharmaceuticals
  7. Sigma Tau
  8. Solvay Pharmaceuticals
  9. Sticares InterACT
  10. Takeda Pharmaceuticals North America, Inc.

向作者/读者索取更多资源

Heart failure is a pressing public health problem with no curative treatment currently available. The existing therapies provide symptomatic relief, but are unable to reverse molecular changes that occur in cardiomyocytes. The mechanisms of heart failure are complex and multiple, but mitochondrial dysfunction appears to be a critical factor in the development of this disease. Thus, it is important to focus research efforts on targeting mitochondrial dysfunction in the failing heart to revive the myocardium and its contractile function. This review highlights the 3 promising areas for the development of heart failure therapies, including mitochondrial biogenesis, mitochondrial oxidative stress, and mitochondrial iron handling. Moreover, the translational potential of compounds targeting these pathways is discussed. (J Am Coll Cardiol 2013;61:599-610) (C) 2013 by the American College of Cardiology Foundation

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据